RSV shots from GSK, Pfizer get potential boost from broadened ACIP guidance
A year after narrowing its recommendation for who should use vaccines to defend against respiratory syncytial virus, a panel of experts advising the Centers for Disease Control and Prevention (CDC) has expanded its endorsement. The reversal from the Advisory Committee on Immunization Practices is a potential boost for GSK and Pfizer.
A year after narrowing its recommendation for who should use vaccines to defend against respiratory syncytial virus, a panel of experts advising the Centers for Disease Control and Prevention (CDC) has expanded its endorsement. The reversal from the Advisory Committee on Immunization Practices is a potential boost for GSK and Pfizer.
